Welcome to our dedicated page for Cue Health news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health stock.
Cue Health Inc. (HLTH) delivers innovative at-home diagnostic solutions through its integrated platform of molecular testing and mobile health technology. This news hub provides investors and stakeholders with essential updates about the company’s financial performance, product developments, and strategic initiatives.
Access timely announcements including quarterly earnings reports, FDA clearances, partnership agreements, and research breakthroughs. Our curated collection ensures you stay informed about HLTH’s advancements in digital health diagnostics without speculative commentary.
Key updates cover regulatory milestones, new test kit approvals, executive leadership changes, and scientific validation studies. Each release maintains focus on verifiable facts about the company’s patented technology and market position.
Bookmark this page for direct access to primary source materials about Cue Health’s progress in transforming personal health monitoring. Check regularly for objective updates on their mobile-integrated diagnostic ecosystem and business developments.
Cue Health (Nasdaq: HLTH) has partnered with the Minnesota Department of Health to offer a COVID-19 telehealth-to-treatment program at no cost. This service allows Minnesota residents who test positive for COVID-19 to consult healthcare professionals virtually and obtain prescriptions for treatment. The program provides same-day treatment access through local pharmacies, regardless of insurance status. Cue's COVID-19 test is renowned for its accuracy, with a 97.8% concordance rate with PCR tests, making it a critical tool in pandemic response.
Cue Health (Nasdaq: HLTH) has expanded its Board of Directors with the addition of Josh Ghaim, Ph.D., and Sachin Jain, M.D. This brings the total number of directors to seven, with five being independent. Ghaim is noted for his extensive experience in digital health and past role as Chief Technology Officer at Johnson & Johnson Consumer Health, while Jain is recognized for his leadership in healthcare innovation and current position as CEO of SCAN Group. This change aims to enhance Cue's strategic focus on making healthcare more accessible and timely.
Cue Health Inc. (Nasdaq: HLTH) reported Q3 2022 revenue of $69.6 million, surpassing expectations, driven largely by COVID-19 testing. The company submitted multiple tests for FDA clearance, including Flu A/B and a multiplex test for Flu A/B + COVID. Despite strong sales, Cue reported a GAAP net loss of $66.3 million and adjusted losses also reflected significant operational expenses of $86.4 million. Cash reserves stood at $304.7 million. Guidance for Q4 2022 forecasts revenue between $45 million and $50 million.
Cue Health Inc. (Nasdaq: HLTH) will release its third quarter 2022 financial results on November 9, 2022. A conference call and webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent highlights. Investors can register for the live call online, and a replay will be available afterward on the company’s website. Cue Health, a healthcare technology company, specializes in accessible health information and diagnostics, with products including the first FDA-authorized at-home COVID-19 test.
Cue Health Inc. (Nasdaq: HLTH) partners with actress Jamie-Lynn Sigler to promote its Cue Care™ test-to-treatment service for COVID-19. This service allows individuals who test positive for COVID-19 to consult healthcare professionals virtually and receive prescription treatments delivered to their home through the Cue Health App. Cue and Sigler are donating Cue Readers and COVID-19 tests to the Multiple Sclerosis Association of America (MSAA), enabling home-testing for those at risk, particularly individuals with multiple sclerosis. Cue's COVID-19 test is recognized as the most accurate self-test in the U.S.
On September 27, 2022, Cue Health (Nasdaq: HLTH) appointed Suzanne Stone as its new Chief Commercial Officer. With over 25 years in the biotech and medical device sectors, Stone previously served as Senior Vice President at DexCom, where she managed nearly $2 billion in revenue. Her role at Cue will involve leading global commercial strategies and enhancing marketing initiatives. CEO Ayub Khattak emphasized the importance of her leadership in strengthening Cue's market position and growth in key customer categories.
Cue Health has appointed David Tsay, MD, PhD, as its new Chief Medical Officer. Dr. Tsay brings over 20 years of experience from his previous roles at Apple and New York-Presbyterian, where he led digital transformation initiatives. At Cue, he will define future diagnostic products and enhance collaboration across healthcare stakeholders. His expertise aims to advance Cue's mission of democratizing diagnostic testing, ultimately improving health outcomes. Cue Health, traded as HLTH, focuses on providing real-time health information and diagnostics.
Cue Health (Nasdaq: HLTH) announced a de novo submission to the FDA for full clearance of its Cue® Flu Molecular Test, the first at-home flu test reviewed for safety and effectiveness. The clinical study indicated 99% accuracy compared to existing lab tests for influenza A&B. This test aims to facilitate early detection and treatment, aligning with Cue's strategy of innovation in diagnostics. The company's COVID-19 test remains under FDA de novo review. With over 250,000 Cue Readers in use, Cue Health is positioned as a leader in accessible health diagnostics.
Cue Health (Nasdaq: HLTH) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 p.m. Eastern Time, in New York, NY. The event will be accessible via a live audio webcast and can be replayed for 180 days on the company’s website. Cue Health focuses on providing accessible health information and diagnostics, including a notable at-home COVID-19 test with FDA approval. Founded in 2010, the company is headquartered in San Diego.
On August 29, 2022, Cue Health Inc. (Nasdaq: HLTH) launched Cue Care™, a nationwide service providing same-day, at-home test-to-treatment solutions for COVID-19. Patients testing positive can consult healthcare professionals virtually, obtain e-prescriptions, and receive medication delivery, usually within hours, at a cost of $79 to $99. This service will soon extend to other diagnostic tests like flu and strep throat. Cue Health's COVID-19 test is noted for its accuracy, delivering results in 20 minutes and is endorsed by various prestigious organizations.
